Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, not necessarily linked to gain and the implications sustainability of their healthcare systems.Areas covered: Narrative discussion principally payers advisers potential approaches pricing medicines.Expert opinion: A number discussed including minimum effectiveness levels managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair models, amortization models as well de-linkage models. We likely see a growth in alternative deliberations view ongoing challenges. These include considerable oncology medicines development gene therapies, being launched with uncertainty value, continued high coupled extent confidential discounts reimbursement. However, balanced against need medicines. This will lead greater scrutiny over patent more standard lose patent, calls transparency be monitoring these developments.